[
  {
    "title": "博瑞医药(688166.SH)：各募投项目正按计划积极推进中",
    "href": "http://stock.jrj.com.cn/2023/01/02155537253101.shtml",
    "datetime": "2023-01-02 15:55:50",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：博瑞新创BGM0504注射液获批开展减重和2型糖尿病适应症临床试验",
    "href": "http://stock.jrj.com.cn/2022/12/29153937246202.shtml",
    "datetime": "2022-12-29 15:39:11",
    "code": "688166"
  },
  {
    "title": "博瑞医药控股股东一致行动人减持422.5万股 套现金额约1亿元",
    "href": "http://stock.jrj.com.cn/2022/12/06103237191137.shtml",
    "datetime": "2022-12-06 10:32:50",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：博瑞鑫稳拟以集中竞价减持不超1%的股份",
    "href": "http://stock.jrj.com.cn/2022/12/05210837190159.shtml",
    "datetime": "2022-12-05 21:08:58",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：股东钟伟芳完成减持2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/24173637164165.shtml",
    "datetime": "2022-11-24 17:36:19",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)定增结果出炉 汇安基金、垒土资产等4家获配",
    "href": "http://stock.jrj.com.cn/2022/11/23154237160654.shtml",
    "datetime": "2022-11-23 15:42:42",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：吡美莫司原料药获批上市",
    "href": "http://stock.jrj.com.cn/2022/11/17173737147168.shtml",
    "datetime": "2022-11-17 17:37:25",
    "code": "688166"
  },
  {
    "title": "业绩“减速” 大股东减持820万股 博瑞医药巨额研发投入能否换回业绩高增长？",
    "href": "http://stock.jrj.com.cn/2022/11/15090537139482.shtml",
    "datetime": "2022-11-15 09:05:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：实控人拟大宗交易减持公司不超2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/14161737137077.shtml",
    "datetime": "2022-11-14 16:17:41",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：股东钟伟芳拟减持不超2%股份",
    "href": "http://stock.jrj.com.cn/2022/11/14160337137059.shtml",
    "datetime": "2022-11-14 16:03:20",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：以简易程序定增申请获证监会注册批复",
    "href": "http://stock.jrj.com.cn/2022/11/11170237131687.shtml",
    "datetime": "2022-11-11 17:02:53",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：以简易程序定增申请获上交所审核通过",
    "href": "http://stock.jrj.com.cn/2022/10/11160037047063.shtml",
    "datetime": "2022-10-11 16:00:06",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：以简易程序定增申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2022/09/30175837034598.shtml",
    "datetime": "2022-09-30 17:58:30",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：上半年净利润增4.80%至1.12亿元",
    "href": "http://stock.jrj.com.cn/2022/08/24171436930926.shtml",
    "datetime": "2022-08-24 17:14:57",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166)：不向下修正“博瑞转债”转股价格",
    "href": "http://stock.jrj.com.cn/2022/08/17091336906653.shtml",
    "datetime": "2022-08-17 09:13:43",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166)：债券持有人减持公司可转换公司债券",
    "href": "http://stock.jrj.com.cn/2022/07/22101536834785.shtml",
    "datetime": "2022-07-22 10:15:59",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：袁建栋及钟伟芳共减持博瑞转债108.194万张",
    "href": "http://stock.jrj.com.cn/2022/07/21155636831984.shtml",
    "datetime": "2022-07-21 15:56:53",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：注射用米卡芬净钠拟中标集采",
    "href": "http://stock.jrj.com.cn/2022/07/13155836807341.shtml",
    "datetime": "2022-07-13 15:58:55",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：“博瑞转债”将于7月11日起开始转股",
    "href": "http://stock.jrj.com.cn/2022/07/01190936776203.shtml",
    "datetime": "2022-07-01 19:09:33",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：博瑞制药的磷酸奥司他韦干混悬剂获批上市",
    "href": "http://stock.jrj.com.cn/2022/06/22154736749616.shtml",
    "datetime": "2022-06-22 15:47:50",
    "code": "688166"
  },
  {
    "title": "博瑞医药拟募资不超2.22亿元，用于补充流动资金等",
    "href": "http://stock.jrj.com.cn/2022/06/09110336715097.shtml",
    "datetime": "2022-06-09 11:03:33",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166)：2021年年度权益分派调整可转债转股价格",
    "href": "http://stock.jrj.com.cn/2022/06/09100336714863.shtml",
    "datetime": "2022-06-09 10:03:38",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟2000万元转让彩科生物2.42%的股权",
    "href": "http://stock.jrj.com.cn/2022/06/08174436712977.shtml",
    "datetime": "2022-06-08 17:44:01",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟将博泽格霖49%股权转让给博诺康源",
    "href": "http://stock.jrj.com.cn/2022/05/31195236694424.shtml",
    "datetime": "2022-05-31 19:52:57",
    "code": "688166"
  },
  {
    "title": "博瑞医药2022年第一季度净利6075.44万同比增长25% 主营业务量增长",
    "href": "http://stock.jrj.com.cn/2022/05/03191136546533.shtml",
    "datetime": "2022-05-03 19:11:49",
    "code": "688166"
  },
  {
    "title": "博瑞医药披露2022年一季报 实现营收2.48亿元",
    "href": "http://stock.jrj.com.cn/2022/04/28114136491704.shtml",
    "datetime": "2022-04-28 11:41:40",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)一季度净利润6075.44万元 同比增长25%",
    "href": "http://stock.jrj.com.cn/2022/04/27161736484422.shtml",
    "datetime": "2022-04-27 16:17:26",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：2021年净利增43.60%至2.44亿元 拟10派1.2元",
    "href": "http://stock.jrj.com.cn/2022/04/15191736346264.shtml",
    "datetime": "2022-04-15 19:17:49",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：先进制造基金减持到期未减持",
    "href": "http://stock.jrj.com.cn/2022/04/13170336324519.shtml",
    "datetime": "2022-04-13 17:03:32",
    "code": "688166"
  },
  {
    "title": "全球首家！博瑞医药(688166.SH)恩替卡韦片通过WHO的PQ认证",
    "href": "http://stock.jrj.com.cn/2022/03/23174434869589.shtml",
    "datetime": "2022-03-23 17:44:52",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：博瑞香港拟向博瑞印尼增资48.30万美元",
    "href": "http://stock.jrj.com.cn/2022/03/07171934538117.shtml",
    "datetime": "2022-03-07 17:19:40",
    "code": "688166"
  },
  {
    "title": "博瑞医药2021年净利2.44亿 同比增加43% 持续打造高技术壁垒",
    "href": "http://stock.jrj.com.cn/2022/02/25205134468415.shtml",
    "datetime": "2022-02-25 20:51:34",
    "code": "688166"
  },
  {
    "title": "A股异动 | 27家药企获准仿制默沙东新冠口服药 复星医药、博瑞医药双双涨停",
    "href": "http://stock.jrj.com.cn/2022/01/21093334181173.shtml",
    "datetime": "2022-01-21 09:33:32",
    "code": "688166"
  },
  {
    "title": "五家中国企业获授权免费仿制默沙东口服新冠药，A股复星医药、博瑞医药双双涨停，港股维亚生物高开15％",
    "href": "http://stock.jrj.com.cn/2022/01/21092834181107.shtml",
    "datetime": "2022-01-21 09:28:48",
    "code": "688166"
  },
  {
    "title": "开盘：A股三大指数集体低开沪指跌0.23%，复星医药、博瑞医药双双涨停",
    "href": "http://stock.jrj.com.cn/2022/01/21092734181099.shtml",
    "datetime": "2022-01-21 09:27:06",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟使用总额不超3.5亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/01/20155134178547.shtml",
    "datetime": "2022-01-20 15:51:39",
    "code": "688166"
  },
  {
    "title": "博瑞医药股东红杉智盛减持822.51万股 套现2.65亿 2021年第三季度公司净利7000.47万",
    "href": "http://stock.jrj.com.cn/2022/01/18205134171257.shtml",
    "datetime": "2022-01-18 20:51:11",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：减持期届满 红杉智盛已减持822.51万股",
    "href": "http://stock.jrj.com.cn/2022/01/18173934170277.shtml",
    "datetime": "2022-01-18 17:39:36",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：减持期过半 先进制造基金未减持股份",
    "href": "http://stock.jrj.com.cn/2022/01/13165834154458.shtml",
    "datetime": "2022-01-13 16:58:29",
    "code": "688166"
  },
  {
    "title": "博瑞医药发布对外投资暨关联交易 投资金额1000万元",
    "href": "http://stock.jrj.com.cn/invest/2021/12/30092634086106.shtml",
    "datetime": "2021-12-30 09:26:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟出资1000万元参与对保易制药增资",
    "href": "http://stock.jrj.com.cn/2021/12/29213834083059.shtml",
    "datetime": "2021-12-29 21:38:31",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：可转债网上路演时间为12月31日10:00-11:00",
    "href": "http://stock.jrj.com.cn/2021/12/29184734082334.shtml",
    "datetime": "2021-12-29 18:47:54",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：注射用BGC0228开展晚期恶性肿瘤的临床试验获批",
    "href": "http://stock.jrj.com.cn/2021/12/10194633995759.shtml",
    "datetime": "2021-12-10 19:46:20",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：2838.46万股限售股将于12月10日解禁上市",
    "href": "http://stock.jrj.com.cn/2021/12/02172133955866.shtml",
    "datetime": "2021-12-02 17:21:04",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：红杉智盛已通过大宗交易减持439.28万股",
    "href": "http://stock.jrj.com.cn/2021/11/25163833919143.shtml",
    "datetime": "2021-11-25 16:38:05",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：发行可转债申请获得证监会同意注册批复",
    "href": "http://stock.jrj.com.cn/2021/11/17160533866357.shtml",
    "datetime": "2021-11-17 16:05:02",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：第三季度净利润升45.81%至7000.47万元",
    "href": "http://stock.jrj.com.cn/2021/10/25163433747455.shtml",
    "datetime": "2021-10-25 16:34:11",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：发行可转债申请获上交所审核通过",
    "href": "http://stock.jrj.com.cn/2021/10/12182633680407.shtml",
    "datetime": "2021-10-12 18:26:24",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：先进制造基金拟减持不超2%的股份",
    "href": "http://stock.jrj.com.cn/2021/09/30171433543690.shtml",
    "datetime": "2021-09-30 17:14:57",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：选举袁建栋为董事长、聘任邹元来为财务总监",
    "href": "http://stock.jrj.com.cn/2021/09/27193733525223.shtml",
    "datetime": "2021-09-27 19:37:21",
    "code": "688166"
  },
  {
    "title": "A股异动 | 博瑞医药(688166.SH)跌逾6%创逾一年半新低 红杉智盛拟减持不超2.02%股份",
    "href": "http://stock.jrj.com.cn/2021/09/16111433444286.shtml",
    "datetime": "2021-09-16 11:14:07",
    "code": "688166"
  },
  {
    "title": "博瑞医药股东红杉智盛拟减持不超828.8万股公司股份 上半年公司净利1.07亿",
    "href": "http://stock.jrj.com.cn/2021/09/15202233441107.shtml",
    "datetime": "2021-09-15 20:22:44",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：红杉智盛拟减持不超2.02%股份",
    "href": "http://stock.jrj.com.cn/2021/09/15171533440177.shtml",
    "datetime": "2021-09-15 17:15:23",
    "code": "688166"
  },
  {
    "title": "博瑞医药：王征野辞去董事会秘书职务",
    "href": "http://stock.jrj.com.cn/2021/09/10201233416848.shtml",
    "datetime": "2021-09-10 20:12:00",
    "code": "688166"
  },
  {
    "title": "A股异动丨博瑞医药(688166.SH)放量升超8% 中期净利增长45%至1.07亿元",
    "href": "http://stock.jrj.com.cn/2021/08/25145433315996.shtml",
    "datetime": "2021-08-25 14:54:40",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：上半年净利增44.96%至1.07亿元",
    "href": "http://stock.jrj.com.cn/2021/08/24194933311505.shtml",
    "datetime": "2021-08-24 19:49:29",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：博瑞制药通过药品GMP符合性检查",
    "href": "http://stock.jrj.com.cn/2021/08/10165833232073.shtml",
    "datetime": "2021-08-10 16:58:19",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：获得“磷酸奥司他韦胶囊”的药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/08/02163933189446.shtml",
    "datetime": "2021-08-02 16:39:26",
    "code": "688166"
  },
  {
    "title": "博瑞医药可转债遭问询：融资规模、股权投资被关注",
    "href": "http://stock.jrj.com.cn/2021/07/26112933151400.shtml",
    "datetime": "2021-07-26 11:29:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：发行可转债申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2021/07/05163533047629.shtml",
    "datetime": "2021-07-05 16:35:56",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：子公司注射用米卡芬净钠通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2021/06/28180233010985.shtml",
    "datetime": "2021-06-28 18:02:19",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：子公司博瑞香港拟对博瑞印尼增资330万美元",
    "href": "http://stock.jrj.com.cn/2021/04/21160032416382.shtml",
    "datetime": "2021-04-21 16:00:20",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)拟发行可转债募资不超7.15亿元",
    "href": "http://stock.jrj.com.cn/2021/03/26175432223534.shtml",
    "datetime": "2021-03-26 17:54:10",
    "code": "688166"
  },
  {
    "title": "博瑞医药及博瑞制药通过高新技术企业重新认定",
    "href": "http://stock.jrj.com.cn/2021/03/25090832213550.shtml",
    "datetime": "2021-03-25 09:08:54",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)及子公司博瑞制药通过高新技术企业重新认定",
    "href": "http://stock.jrj.com.cn/2021/03/24162132208862.shtml",
    "datetime": "2021-03-24 16:21:45",
    "code": "688166"
  },
  {
    "title": "博瑞医药去年赚近1.7亿 派现比例占比仅两成",
    "href": "http://stock.jrj.com.cn/2021/03/23101832199969.shtml",
    "datetime": "2021-03-23 10:18:45",
    "code": "688166"
  },
  {
    "title": "博瑞医药2020年净利1.7亿增长52.93%管理费用增长 董事长袁建栋薪酬150.80万",
    "href": "http://stock.jrj.com.cn/2021/03/22214032196821.shtml",
    "datetime": "2021-03-22 21:40:10",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)2020年度净利润升52.93%至1.7亿元 拟10派0.84元",
    "href": "http://stock.jrj.com.cn/2021/03/22181532195750.shtml",
    "datetime": "2021-03-22 18:15:29",
    "code": "688166"
  },
  {
    "title": "博瑞医药：全资子公司博瑞制药获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/03/19090532161645.shtml",
    "datetime": "2021-03-19 09:05:25",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：奥拉西坦注射液获药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/03/18154232157061.shtml",
    "datetime": "2021-03-18 15:42:48",
    "code": "688166"
  },
  {
    "title": "博瑞医药2020年度净利1.7亿增长53.11% 主营业务收入增加",
    "href": "http://stock.jrj.com.cn/2021/02/24182032019842.shtml",
    "datetime": "2021-02-24 18:20:50",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：向84名激励对象授予200万股限制性股票",
    "href": "http://stock.jrj.com.cn/2021/02/08204531872171.shtml",
    "datetime": "2021-02-08 20:45:47",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2020年归母净利润、扣非净利润均预增45%到60%",
    "href": "http://stock.jrj.com.cn/2021/01/26114031775219.shtml",
    "datetime": "2021-01-26 11:40:24",
    "code": "688166"
  },
  {
    "title": "博瑞医药2020年预计净利1.61亿-1.78亿增加45%-60% 生产能力和产品质量保持稳定",
    "href": "http://stock.jrj.com.cn/2021/01/25175031767046.shtml",
    "datetime": "2021-01-25 17:50:41",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟向激励对象授予限制性股票200万股",
    "href": "http://stock.jrj.com.cn/2021/01/20174831730132.shtml",
    "datetime": "2021-01-20 17:48:24",
    "code": "688166"
  },
  {
    "title": "[博济医药]博济医药正式任命袁智博士为子公司深圳博瑞医药副总经理",
    "href": "http://stock.jrj.com.cn/2021/01/07000031673806.shtml",
    "datetime": "2021-01-07 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟使用不超2亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2020/12/11184731466344.shtml",
    "datetime": "2020-12-11 18:47:58",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]布局吸入,畅游蓝海 | 博瑞医药高端原料药山东基地顺利奠基",
    "href": "http://stock.jrj.com.cn/2020/11/30000031376408.shtml",
    "datetime": "2020-11-30 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药全资子公司拟签订项目投资协议 两个项目总投资金额约13亿元",
    "href": "http://stock.jrj.com.cn/2020/11/13210731277710.shtml",
    "datetime": "2020-11-13 21:07:37",
    "code": "688166"
  },
  {
    "title": "博瑞医药：拟在泰兴经开区投建原料药、高端制剂项目 合计总投资约13亿元",
    "href": "http://stock.jrj.com.cn/2020/11/13173931276443.shtml",
    "datetime": "2020-11-13 17:39:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)：拟扩大公司经营范围",
    "href": "http://stock.jrj.com.cn/2020/11/13161631275897.shtml",
    "datetime": "2020-11-13 16:16:37",
    "code": "688166"
  },
  {
    "title": "博瑞医药(688166.SH)签订2个项目投资协议 总投资约13亿元",
    "href": "http://stock.jrj.com.cn/2020/11/13161531275899.shtml",
    "datetime": "2020-11-13 16:15:44",
    "code": "688166"
  },
  {
    "title": "博瑞医药前三季度净利增长超九成 高端仿制药仍为蓝海领域",
    "href": "http://stock.jrj.com.cn/2020/10/26000031123983.shtml",
    "datetime": "2020-10-26 00:00:39",
    "code": "688166"
  },
  {
    "title": "博瑞医药前三季度净利1.22亿增长90.89% 产品销售收入大幅增长",
    "href": "http://stock.jrj.com.cn/2020/10/23091131113862.shtml",
    "datetime": "2020-10-23 09:11:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/23001031111804.shtml",
    "datetime": "2020-10-23 00:10:12",
    "code": "688166"
  },
  {
    "title": "博瑞医药2020年上半年净利7372.26万增长78.27% 主营业务量增加明显",
    "href": "http://stock.jrj.com.cn/2020/08/18124030528829.shtml",
    "datetime": "2020-08-18 12:40:02",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]博瑞医药入选“2019江苏省百强创新型企业”",
    "href": "http://stock.jrj.com.cn/2020/07/02000030867110.shtml",
    "datetime": "2020-07-02 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药收监管工作函股价下挫 今年来4收监管文书",
    "href": "http://stock.jrj.com.cn/2020/07/01114230109308.shtml",
    "datetime": "2020-07-01 11:42:00",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]扬帆起航 | 博瑞医药恩替卡韦片出口美国市场",
    "href": "http://stock.jrj.com.cn/2020/06/30000030867114.shtml",
    "datetime": "2020-06-30 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药拟9000万元发起设立投资基金",
    "href": "http://stock.jrj.com.cn/2020/06/24220630012788.shtml",
    "datetime": "2020-06-24 22:06:07",
    "code": "688166"
  },
  {
    "title": "博瑞医药参与发起设立投资基金 基金募集规模为3亿元",
    "href": "http://stock.jrj.com.cn/2020/06/24220230012755.shtml",
    "datetime": "2020-06-24 22:02:27",
    "code": "688166"
  },
  {
    "title": "博瑞医药恩替卡韦原料药获得欧洲CEP证书",
    "href": "http://stock.jrj.com.cn/2020/06/22183629990108.shtml",
    "datetime": "2020-06-22 18:36:46",
    "code": "688166"
  },
  {
    "title": "快讯：博瑞医药急速拉升7.41% 主力资金净流入354.01万元(dev)",
    "href": "http://stock.jrj.com.cn/2020/06/22154829988947.shtml",
    "datetime": "2020-06-22 15:48:42",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]蓄势待发 | 博瑞医药获批恩替卡韦CEP证书",
    "href": "http://stock.jrj.com.cn/2020/06/22000030867112.shtml",
    "datetime": "2020-06-22 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/12233029653964.shtml",
    "datetime": "2020-05-12 23:30:00",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]共筑未来,再绘精彩 | 博瑞医药泰兴新生产基地奠基仪式圆满成功",
    "href": "http://stock.jrj.com.cn/2020/05/08000030867109.shtml",
    "datetime": "2020-05-08 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：首次公开发行网下配售限售股上市流通公告",
    "href": "http://stock.jrj.com.cn/2020/04/26221029379263.shtml",
    "datetime": "2020-04-26 22:10:07",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2020年第一季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/19233029321630.shtml",
    "datetime": "2020-04-19 23:30:02",
    "code": "688166"
  },
  {
    "title": "博瑞医药：关于召开2019年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/04/19233029321631.shtml",
    "datetime": "2020-04-19 23:30:02",
    "code": "688166"
  },
  {
    "title": "博瑞医药监事陈淼辞职 因个人原因",
    "href": "http://stock.jrj.com.cn/2020/04/19215829321370.shtml",
    "datetime": "2020-04-19 21:58:58",
    "code": "688166"
  },
  {
    "title": "公告精选：西麦食品拟10转10派16元；博瑞医药等一季度净利大增",
    "href": "http://stock.jrj.com.cn/2020/04/19203329321122.shtml",
    "datetime": "2020-04-19 20:33:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：一季度净利同比增111%",
    "href": "http://stock.jrj.com.cn/2020/04/19150329320464.shtml",
    "datetime": "2020-04-19 15:03:00",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]博瑞医药「注射用米卡芬净钠」获批上市",
    "href": "http://stock.jrj.com.cn/2020/04/17000030867111.shtml",
    "datetime": "2020-04-17 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药子公司获得注射用米卡芬净钠药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/04/16211729307354.shtml",
    "datetime": "2020-04-16 21:17:27",
    "code": "688166"
  },
  {
    "title": "博瑞医药：获得注射用米卡芬净钠药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/04/16202429307067.shtml",
    "datetime": "2020-04-16 20:24:00",
    "code": "688166"
  },
  {
    "title": "社保、养老金掘金科创板 金山办公博瑞医药等受青睐",
    "href": "http://stock.jrj.com.cn/2020/04/16065229300903.shtml",
    "datetime": "2020-04-16 06:52:00",
    "code": "688166"
  },
  {
    "title": "技术转让收益增长强势 博瑞医药去年净利润同比增长51.75%",
    "href": "http://stock.jrj.com.cn/2020/04/10195529259297.shtml",
    "datetime": "2020-04-10 19:55:34",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/09231029250103.shtml",
    "datetime": "2020-04-09 23:10:01",
    "code": "688166"
  },
  {
    "title": "[博瑞医药]博瑞医药签署仿制药开发和商业化独家合作协议 海外项目开拓获突破",
    "href": "http://stock.jrj.com.cn/2020/04/01000030867113.shtml",
    "datetime": "2020-04-01 00:00:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药拟与美国公司合作开发甲磺酸艾立布林注射液仿制药",
    "href": "http://stock.jrj.com.cn/2020/03/31222029161098.shtml",
    "datetime": "2020-03-31 22:20:39",
    "code": "688166"
  },
  {
    "title": "博瑞医药：拟与美国公司合作开发甲磺酸艾立布林注射液仿制药",
    "href": "http://stock.jrj.com.cn/2020/03/31205729160564.shtml",
    "datetime": "2020-03-31 20:57:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：签署独家合作协议",
    "href": "http://stock.jrj.com.cn/2020/03/31202829160346.shtml",
    "datetime": "2020-03-31 20:28:51",
    "code": "688166"
  },
  {
    "title": "博瑞医药蹭热点信披不准 公司及董秘王征野吃警示函",
    "href": "http://stock.jrj.com.cn/2020/03/17113629043409.shtml",
    "datetime": "2020-03-17 11:36:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：公司及董事会秘书收到江苏证监局警示函",
    "href": "http://stock.jrj.com.cn/2020/03/12191429011293.shtml",
    "datetime": "2020-03-12 19:14:31",
    "code": "688166"
  },
  {
    "title": "博瑞医药：公司及高管收到江苏证监局警示函",
    "href": "http://stock.jrj.com.cn/2020/03/12190729011228.shtml",
    "datetime": "2020-03-12 19:07:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：公司及董事会秘书王征野被江苏证监局出具警示函",
    "href": "http://stock.jrj.com.cn/2020/03/12185029011151.shtml",
    "datetime": "2020-03-12 18:50:42",
    "code": "688166"
  },
  {
    "title": "“批量生产”瑞德西韦有误 博瑞医药到底能不能量产抗病毒药？",
    "href": "http://stock.jrj.com.cn/2020/03/02174728935461.shtml",
    "datetime": "2020-03-02 17:47:14",
    "code": "688166"
  },
  {
    "title": "强蹭瑞德西韦热点市值暴增百亿！博瑞医药董秘王征野遭监管批评 曾从医院下海从事多年医药销售",
    "href": "http://stock.jrj.com.cn/2020/03/02110928932912.shtml",
    "datetime": "2020-03-02 11:09:56",
    "code": "688166"
  },
  {
    "title": "博瑞医药蹭瑞德西韦热点遭监管关注 董秘王征野遭批评",
    "href": "http://stock.jrj.com.cn/2020/03/02110328932907.shtml",
    "datetime": "2020-03-02 11:03:00",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药开盘跌停",
    "href": "http://stock.jrj.com.cn/2020/03/02093528930403.shtml",
    "datetime": "2020-03-02 09:35:00",
    "code": "688166"
  },
  {
    "title": "强蹭瑞德西韦 号称2周完成研发并量产！这家上市公司市值暴增77亿 却被无情拆穿",
    "href": "http://stock.jrj.com.cn/2020/03/02072828928005.shtml",
    "datetime": "2020-03-02 07:28:27",
    "code": "688166"
  },
  {
    "title": "“瑞德西韦”概念下市值暴涨百亿 博瑞医药信披被指违规",
    "href": "http://stock.jrj.com.cn/2020/03/01232128922409.shtml",
    "datetime": "2020-03-01 23:21:41",
    "code": "688166"
  },
  {
    "title": "博瑞医药“批量化生产瑞德西韦”的信披不准确 上交所对该公司及其时任董秘予以监管关注",
    "href": "http://stock.jrj.com.cn/2020/03/01202928922158.shtml",
    "datetime": "2020-03-01 20:29:00",
    "code": "688166"
  },
  {
    "title": "强行蹭“瑞德西韦”热点 上交所对博瑞医药予以监管关注",
    "href": "http://stock.jrj.com.cn/kcb/2020/03/01180128921818.shtml",
    "datetime": "2020-03-01 18:01:18",
    "code": "688166"
  },
  {
    "title": "博瑞医药2019年盈利1.11亿元增长52% 综合毛利率有所提高",
    "href": "http://stock.jrj.com.cn/2020/02/25184928891465.shtml",
    "datetime": "2020-02-25 18:49:26",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年净利1.11亿元 同比增长52%",
    "href": "http://stock.jrj.com.cn/2020/02/25173128891064.shtml",
    "datetime": "2020-02-25 17:31:30",
    "code": "688166"
  },
  {
    "title": "博瑞医药业绩快报：2019年净利1.11亿元 同比增52%",
    "href": "http://stock.jrj.com.cn/2020/02/25172228891030.shtml",
    "datetime": "2020-02-25 17:22:00",
    "code": "688166"
  },
  {
    "title": "医药板块热度减退 博瑞医药仿制瑞德西韦引关注",
    "href": "http://stock.jrj.com.cn/2020/02/15140428833213.shtml",
    "datetime": "2020-02-15 14:04:24",
    "code": "688166"
  },
  {
    "title": "博瑞医药涨超15% 振幅超30%",
    "href": "http://stock.jrj.com.cn/2020/02/14102528828227.shtml",
    "datetime": "2020-02-14 10:25:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药大幅回调 跌超12%",
    "href": "http://stock.jrj.com.cn/2020/02/14093828827981.shtml",
    "datetime": "2020-02-14 09:38:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：公司关于瑞德西韦的开发工作尚处于研发阶段 不存在侵犯专利权的情形",
    "href": "http://stock.jrj.com.cn/2020/02/13191528825199.shtml",
    "datetime": "2020-02-13 19:15:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：瑞德西韦的开发工作尚处于研发阶段",
    "href": "http://stock.jrj.com.cn/2020/02/13190328825149.shtml",
    "datetime": "2020-02-13 19:03:35",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药开盘继续涨停 两天涨44%",
    "href": "http://stock.jrj.com.cn/2020/02/13093328821487.shtml",
    "datetime": "2020-02-13 09:33:00",
    "code": "688166"
  },
  {
    "title": "火速开发生产瑞德西韦仿制药 科创板博瑞医药连续两日涨停",
    "href": "http://stock.jrj.com.cn/2020/02/13093128821435.shtml",
    "datetime": "2020-02-13 09:31:17",
    "code": "688166"
  },
  {
    "title": "博瑞医药开始生产瑞德西韦制剂 称“我们不会靠这个盈利”",
    "href": "http://stock.jrj.com.cn/2020/02/13073028820875.shtml",
    "datetime": "2020-02-13 07:30:14",
    "code": "688166"
  },
  {
    "title": "博瑞医药董秘王征野：瑞德西韦制剂今天开始生产 不会发国难财",
    "href": "http://stock.jrj.com.cn/2020/02/12142628815282.shtml",
    "datetime": "2020-02-12 14:26:05",
    "code": "688166"
  },
  {
    "title": "博瑞医药回复瑞德西韦仿制药：将召开情况说明会 时间待定",
    "href": "http://stock.jrj.com.cn/2020/02/12134228815103.shtml",
    "datetime": "2020-02-12 13:42:51",
    "code": "688166"
  },
  {
    "title": "博瑞医药成功仿制瑞德西韦 董秘称不会在这上面赚钱",
    "href": "http://stock.jrj.com.cn/2020/02/12112628814542.shtml",
    "datetime": "2020-02-12 11:26:43",
    "code": "688166"
  },
  {
    "title": "博瑞医药开发出瑞德西韦 将无偿捐赠给病人",
    "href": "http://stock.jrj.com.cn/2020/02/12110228818269.shtml",
    "datetime": "2020-02-12 11:02:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药已批量生产瑞德西韦原料药 股价一字涨停",
    "href": "http://stock.jrj.com.cn/2020/02/12104028814279.shtml",
    "datetime": "2020-02-12 10:40:25",
    "code": "688166"
  },
  {
    "title": "博瑞医药一字涨停创新高，称已批量生产出瑞德西韦原料药",
    "href": "http://stock.jrj.com.cn/hotstock/2020/02/12101028814092.shtml",
    "datetime": "2020-02-12 10:10:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药已开始批量生产瑞德西韦制剂 已投入500万还需再投1000万",
    "href": "http://stock.jrj.com.cn/2020/02/12095428814014.shtml",
    "datetime": "2020-02-12 09:54:09",
    "code": "688166"
  },
  {
    "title": "应对疫情！博瑞医药火速开发瑞德西韦 将无偿捐赠给病人",
    "href": "http://stock.jrj.com.cn/2020/02/12094428813967.shtml",
    "datetime": "2020-02-12 09:44:53",
    "code": "688166"
  },
  {
    "title": "博瑞医药开盘涨停 成功仿制开发和生产瑞德西韦原料药",
    "href": "http://stock.jrj.com.cn/2020/02/12093228813864.shtml",
    "datetime": "2020-02-12 09:32:00",
    "code": "688166"
  },
  {
    "title": "已经批量生产出瑞德西韦原料药 科创板博瑞医药开盘涨停",
    "href": "http://stock.jrj.com.cn/2020/02/12092828813775.shtml",
    "datetime": "2020-02-12 09:28:16",
    "code": "688166"
  },
  {
    "title": "科创板公司博瑞医药已批量生产瑞德西韦原料药",
    "href": "http://stock.jrj.com.cn/2020/02/11233428811831.shtml",
    "datetime": "2020-02-11 23:34:55",
    "code": "688166"
  },
  {
    "title": "博瑞医药：瑞德西韦制剂批量化生产正在进行中",
    "href": "http://stock.jrj.com.cn/2020/02/11215028811511.shtml",
    "datetime": "2020-02-11 21:50:40",
    "code": "688166"
  },
  {
    "title": "博瑞医药：公司已经批量生产出瑞德西韦原料药",
    "href": "http://stock.jrj.com.cn/2020/02/11214728811503.shtml",
    "datetime": "2020-02-11 21:47:01",
    "code": "688166"
  },
  {
    "title": "驰援！博瑞医药及董事长共捐200万元现金助力疫情防控",
    "href": "http://stock.jrj.com.cn/2020/01/28154528739383.shtml",
    "datetime": "2020-01-28 15:45:11",
    "code": "688166"
  },
  {
    "title": "博瑞医药及集团董事长共捐200万现金助力疫情防控",
    "href": "http://stock.jrj.com.cn/2020/01/28144128739305.shtml",
    "datetime": "2020-01-28 14:41:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年度业绩预增公告",
    "href": "http://stock.jrj.com.cn/2020/01/17231028695336.shtml",
    "datetime": "2020-01-17 23:10:04",
    "code": "688166"
  },
  {
    "title": "博瑞医药2019年净利预增40%-60%",
    "href": "http://stock.jrj.com.cn/2020/01/17204128694793.shtml",
    "datetime": "2020-01-17 20:41:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年度净利同比预增40%-60%",
    "href": "http://stock.jrj.com.cn/2020/01/17201128694662.shtml",
    "datetime": "2020-01-17 20:11:30",
    "code": "688166"
  },
  {
    "title": "博瑞医药：2019年净利预增40%-60%",
    "href": "http://stock.jrj.com.cn/2020/01/17195128694616.shtml",
    "datetime": "2020-01-17 19:51:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药获得“注射用醋酸卡泊芬净”的《药品注册批件》",
    "href": "http://stock.jrj.com.cn/2020/01/14131328673597.shtml",
    "datetime": "2020-01-14 13:13:42",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获注射用醋酸卡泊芬净药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/01/13214828669279.shtml",
    "datetime": "2020-01-13 21:48:39",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获得注射用醋酸卡泊芬净药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/01/13201528670045.shtml",
    "datetime": "2020-01-13 20:15:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获得药品GMP证书",
    "href": "http://stock.jrj.com.cn/2019/12/18215628552829.shtml",
    "datetime": "2019-12-18 21:56:22",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药：子公司获得药品GMP证书",
    "href": "http://stock.jrj.com.cn/2019/12/18175228552145.shtml",
    "datetime": "2019-12-18 17:52:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司信泰制药获得药品GMP证书",
    "href": "http://stock.jrj.com.cn/2019/12/18175028552005.shtml",
    "datetime": "2019-12-18 17:50:12",
    "code": "688166"
  },
  {
    "title": "博瑞医药：拟3.48亿元投建海外高端制剂药品生产项目",
    "href": "http://stock.jrj.com.cn/2019/12/09192728510046.shtml",
    "datetime": "2019-12-09 19:27:06",
    "code": "688166"
  },
  {
    "title": "博瑞医药：拟3.48亿元投建海外高端制剂药品项目",
    "href": "http://stock.jrj.com.cn/2019/12/09190928509989.shtml",
    "datetime": "2019-12-09 19:09:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获阿尼芬净原料药韩国注册证书",
    "href": "http://stock.jrj.com.cn/2019/12/06174428500564.shtml",
    "datetime": "2019-12-06 17:44:01",
    "code": "688166"
  },
  {
    "title": "博瑞医药获得阿尼芬净原料药韩国注册证书",
    "href": "http://stock.jrj.com.cn/2019/12/06165928500393.shtml",
    "datetime": "2019-12-06 16:59:57",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获得阿尼芬净原料药韩国注册证书",
    "href": "http://stock.jrj.com.cn/2019/12/06165528500351.shtml",
    "datetime": "2019-12-06 16:55:00",
    "code": "688166"
  },
  {
    "title": "专访博瑞医药董秘王征野：伪创新已没有土壤，药企不能靠行贿医生卖药",
    "href": "http://stock.jrj.com.cn/2019/12/03193528484771.shtml",
    "datetime": "2019-12-03 19:35:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药拟使用不超3.8亿元的暂时闲置募集资金现金管理",
    "href": "http://stock.jrj.com.cn/2019/11/29101928466950.shtml",
    "datetime": "2019-11-29 10:19:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获注射用艾司奥美拉唑钠药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/11/27162028458375.shtml",
    "datetime": "2019-11-27 16:20:13",
    "code": "688166"
  },
  {
    "title": "博瑞医药：子公司获磺达肝癸钠注射液药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/11/21165628432776.shtml",
    "datetime": "2019-11-21 16:56:14",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药开盘大涨118%",
    "href": "http://stock.jrj.com.cn/2019/11/08094528369682.shtml",
    "datetime": "2019-11-08 09:45:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药登陆科创板 集合竞价阶段高开118.5%",
    "href": "http://stock.jrj.com.cn/2019/11/08093028369493.shtml",
    "datetime": "2019-11-08 09:30:06",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药中签号出炉 共23370个",
    "href": "http://stock.jrj.com.cn/2019/10/28192028312063.shtml",
    "datetime": "2019-10-28 19:20:00",
    "code": "688166"
  },
  {
    "title": "【兑奖啦】科创板第二波打新盛宴 博瑞医药网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2019/10/28191728311981.shtml",
    "datetime": "2019-10-28 19:17:53",
    "code": "688166"
  },
  {
    "title": "科创板博瑞医药：发行价确定为12.71元/股",
    "href": "http://stock.jrj.com.cn/2019/10/23192728289700.shtml",
    "datetime": "2019-10-23 19:27:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药即将登陆科创板：受红杉智盛中金佳泰青睐 最后一轮融资估值32.5亿",
    "href": "http://stock.jrj.com.cn/2019/10/17231228264134.shtml",
    "datetime": "2019-10-17 23:12:35",
    "code": "688166"
  },
  {
    "title": "博瑞医药实控人袁建栋3229万元养212条锦鲤 上交所要求保荐机构核查",
    "href": "http://stock.jrj.com.cn/2019/10/17193928263190.shtml",
    "datetime": "2019-10-17 19:39:42",
    "code": "688166"
  },
  {
    "title": "证监会同意博瑞医药等5家企业科创板注册 2家系原新三板企业",
    "href": "http://stock.jrj.com.cn/2019/10/14094228241377.shtml",
    "datetime": "2019-10-14 09:42:29",
    "code": "688166"
  },
  {
    "title": "上交所：博瑞医药、华熙生物科创板首发过会",
    "href": "http://stock.jrj.com.cn/2019/08/27171628041506.shtml",
    "datetime": "2019-08-27 17:16:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药将上会 对赌协议被连续追问",
    "href": "http://stock.jrj.com.cn/kcb/2019/08/20035427999085.shtml",
    "datetime": "2019-08-20 03:54:45",
    "code": "688166"
  },
  {
    "title": "科创板上市委：华熙生物、博瑞医药首发事项定于8月27日上会",
    "href": "http://stock.jrj.com.cn/2019/08/16210927989642.shtml",
    "datetime": "2019-08-16 21:09:00",
    "code": "688166"
  },
  {
    "title": "博瑞医药等4企业问询回复“难产”",
    "href": "http://stock.jrj.com.cn/2019/06/13030727696745.shtml",
    "datetime": "2019-06-13 03:07:22",
    "code": "688166"
  },
  {
    "title": "博瑞医药：研发投入占比超20% 带量采购影响几何？",
    "href": "http://stock.jrj.com.cn/2019/05/29071627635499.shtml",
    "datetime": "2019-05-29 07:16:52",
    "code": "688166"
  },
  {
    "title": "最近一轮融资估值逾32亿元 博瑞医药携40多种药物冲刺科创板",
    "href": "http://stock.jrj.com.cn/2019/04/19081027426728.shtml",
    "datetime": "2019-04-19 08:10:50",
    "code": "688166"
  },
  {
    "title": "最近一轮融资估值逾32亿 博瑞医药携40多种药物冲刺科创板",
    "href": "http://stock.jrj.com.cn/2019/04/19050227425906.shtml",
    "datetime": "2019-04-19 05:02:04",
    "code": "688166"
  },
  {
    "title": "博瑞医药闯关科创板 商业模式依赖仿制药企",
    "href": "http://stock.jrj.com.cn/2019/04/16043627402197.shtml",
    "datetime": "2019-04-16 04:36:21",
    "code": "688166"
  },
  {
    "title": "博瑞医药科创板申请获受理 年初刚完成5.5亿融资",
    "href": "http://stock.jrj.com.cn/2019/04/10031927357459.shtml",
    "datetime": "2019-04-10 03:19:32",
    "code": "688166"
  },
  {
    "title": "博瑞医药申请科创板获受理 年初刚完成5.5亿元Pre-IPO轮融资",
    "href": "http://stock.jrj.com.cn/2019/04/09132227359251.shtml",
    "datetime": "2019-04-09 13:22:25",
    "code": "688166"
  }
]